CWBR CohBar is a clinical stage biotechnology company which develops mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases.
CWBR closed few months ago a $15.0 Million Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now.
Cantor Fitzgerald brokerage has a $2.5...
I think antiaging stocks will be the new FAANGS in 5 to 10 years.
Immortality here, on earth, is the next frontier for the medicine.
CohBar is developing mitochondria-based therapeutics for the treatment of chronic and age-related diseases.
On 11/12/2021 Cantor Fitzgerald brokerage Initiated Coverage on CWBR with an Overweight rating and a price target of...
CWBR CohBar is developing mitochondria based therapeutics for the treatment of age-related diseases.
So it`s an anti-aging listed companies.
They released positive topline results from an early stage study into CB4211, a drug under development for the treatment of nonalcoholic steatohepatitis, but after a 70% increase, the stock went even lower than before the...
